I promise I'm not Topexec from the IV board and usually note even a fan of his posts and I know I seem angry and redundant, but...Junius is a failure as CEO. I's time to admit Dan's not the best man for the job and find someone who is better suited to lead this company. This relative under-performance is unacceptable. We don't need 2 CFO's and 4 business developers who don't develop business. Prior to Charlie, I am not sure who was leading in clinical trial design and execution, but they also need to be replaced; assuming it's O'Leary. BOD must do their duty and protect the shareholders from weak, underperforming management
What do you think drove the massive spike up (and the subsequent fall down?). It seems to me that there is interest at the 17 and 18 dollar level, but just not enough volume to support it.
Similar to what you've been saying, I'd love to see some of the stuff that IMGN wants to go all alone on partnered up and accelerated. Wasn't there something coming along from Amgen?